US 11,971,409 B2
Methods of producing patient-specific anti-cancer therapeutics and methods of treatment therefor
Kevin T. Chapman, Emeryville, CA (US); Mark P. White, Orinda, CA (US); Xiaohua Wang, Pomona, NY (US); Minha Park, Brisbane, CA (US); Guido K. Stadler, San Francisco, CA (US); Randall D. Lowe, Jr., Emeryville, CA (US); Xiao Guan Radstrom, San Rafael, CA (US); Jason M. McEwen, El Cerrito, CA (US); Gang F. Wang, Mountain View, CA (US); George L. Fox, Albany, CA (US); and Peggy A. Radel, Berkeley, CA (US)
Assigned to Bruker Cellular Analysis, Inc., Emeryville, CA (US)
Filed by Berkeley Lights, Inc., Emeryville, CA (US)
Filed on Jun. 4, 2020, as Appl. No. 16/892,642.
Application 16/892,642 is a continuation of application No. 15/406,289, filed on Jan. 13, 2017, granted, now 10,712,344.
Claims priority of provisional application 62/279,341, filed on Jan. 15, 2016.
Claims priority of provisional application 62/411,690, filed on Oct. 23, 2016.
Claims priority of provisional application 62/412,092, filed on Oct. 24, 2016.
Prior Publication US 2020/0400669 A1, Dec. 24, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. B01L 3/00 (2006.01); C07K 16/00 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C12Q 1/6886 (2018.01); G01N 33/50 (2006.01); G01N 33/543 (2006.01); G01N 33/569 (2006.01); G01N 33/574 (2006.01)
CPC G01N 33/574 (2013.01) [B01L 3/502761 (2013.01); C07K 16/00 (2013.01); C07K 16/2887 (2013.01); C07K 16/30 (2013.01); C12Q 1/6886 (2013.01); G01N 33/5047 (2013.01); G01N 33/505 (2013.01); G01N 33/5052 (2013.01); G01N 33/54366 (2013.01); G01N 33/56972 (2013.01); B01L 2200/0647 (2013.01); G01N 2800/7028 (2013.01)] 22 Claims
OG exemplary drawing
 
1. A method of identifying an isolated B cell that produces antibodies capable of binding to a cancer cell-associated antigen comprising:
loading a dissociated cell sample from at least one solid tumor sample obtained from a patient into a microfluidic device having at least one flow region and at least one sequestration chamber comprising an isolation region, wherein the isolation region is fluidically connected to the flow region;
moving at least one B cell from the dissociated cell sample into at least one isolation region in the microfluidic device, thereby obtaining at least one isolated B cell; and
identifying at least one isolated B cell that produces antibodies capable of binding to a cancer cell-associated antigen by introducing the cancer cell-associated antigen into the microfluidic device.